(Lung Cancer) Nivolumab + Ipilimumab + Chemotherapy: CheckMate 9LA Trial Results
(Lung Cancer) Nivolumab + Ipilimumab + Chemotherapy: CheckMate 9LA Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Nivolumab + Ipilimumab + Chemotherapy: CheckMate 9LA Trial Results
- June 1, 2020
- 2 min read
From May 29-31, 2020, Martin Reck presented at the ASCO 2020 Virtual Meeting the three-year follow-up efficacy and safety results of anti-PD-1 antibody anti-PD-1 antibody + anti-CTLA-4 antibody anti-CTLA-4 antibody + chemotherapy as first-line treatment for metastatic non-small cell lung cancer patients in the CheckMate-9LA Phase III clinical trial.
The CheckMate-9LA Phase III clinical trial was a multicenter, open-label study that randomized metastatic non-small cell lung cancer patients in a 1:1 ratio into the following two groups. The primary endpoint was overall survival, and secondary endpoints included progression-free survival and objective response rate:
-
anti-PD-1 antibody + anti-CTLA-4 antibody + chemotherapy group (anti-PD-1 antibody 360 mg every three weeks + anti-CTLA-4 antibody 1 mg/kg every six weeks + chemotherapy for up to two cycles).
-
Chemotherapy group (up to four cycles).
At the interim analysis with a median follow-up of 8.1 months, the primary endpoint overall survival showed improvement in the anti-PD-1 antibody + anti-CTLA-4 antibody + chemotherapy group compared with the chemotherapy group. At a median follow-up of 12.7 months, the median overall survival was 15.6 months for the anti-PD-1 antibody + anti-CTLA-4 antibody + chemotherapy group / 10.9 months for the chemotherapy group, demonstrating improvement.
Regarding safety, the adverse events in the anti-PD-1 antibody + anti-CTLA-4 antibody + chemotherapy group were consistent with the known safety profile from existing clinical trials, and no new adverse events were identified in this trial.
Based on the CheckMate-9LA trial results, Martin Reck concluded that using anti-PD-1 antibody anti-PD-1 antibody + anti-CTLA-4 antibody anti-CTLA-4 antibody plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer patients confirmed improvement in overall survival.
[Disclaimer] The clinical trial data and pharmaceutical information translated by "Medical Supporter" from overseas studies are not intended to encourage participation in clinical trials or use of new drugs. The translated materials are for reference only and do not constitute medication guidelines. Please consult with healthcare professionals, and refer to the original text below for accurate content.
Source: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. (2020 ASCO VIRTUAL SCIENTIFIC PROGRAM, Abstract No: 9501)
-
Immunotherapy
-
Investigational drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.